Country
Switzerland
Faricimab, a bispecific antibody for neovascular age-related macular degeneration, has met its non-inferiority endpoint in two Phase 3 trials, the developer Roche announced on 25 January.
Full text available to subscribers only. Click here for information on subscribing to MedNous.